Sugi Predict

Sugi Predict / Compounds / SCHEMBL2292608

SCHEMBL2292608

SCHEMBL2292608

CC(C)(C)OC(=O)N1CC2=C(C1)CN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ ESR2 Q92731 1/20 0.45
▸ NR1H2 P55055 4/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ NAMPT P43490 1/20 0.43
▸ HDAC1 Q13547 1/20 0.42
▸ DDB1 Q16531 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42
▸ GPR119 Q8TDV5 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17629419 0.92 USP2 (0.46) USP2SMN1; SMN2ESR2NR1H2MAPK1
SCHEMBL14043923 0.92 USP2 (0.46) USP2SMN1; SMN2ESR2NR1H2MAPK1
SCHEMBL17611204 0.92 USP2 (0.46) USP2SMN1; SMN2ESR2NR1H2MAPK1
SCHEMBL18668387 0.90 USP2 (0.44) USP2SMN1; SMN2ESR2NR1H2MAPK1
SCHEMBL25770783 0.89 USP2 (0.43) USP2SMN1; SMN2ESR2NR1H2MAPK1
SCHEMBL1394242 0.86 USP2 (0.44) USP2SMN1; SMN2ESR2NR1H2MAPK1
SCHEMBL17629416 0.86 GPR119 (0.42) USP2SMN1; SMN2ESR2NR1H2MAPK1
Hydrochloric Acid SCHEMBL18668391 0.85 USP2 (0.43) USP2SMN1; SMN2ESR2NR1H2MAPK1
SCHEMBL120243 0.84 USP2 (0.50) USP2SMN1; SMN2ESR2NR1H2MAPK1
SCHEMBL17080478 0.84 USP2 (0.50) USP2SMN1; SMN2ESR2NR1H2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111196806-B Guanidine derivative and application thereof 广东东阳光药业股份有限公司 2024-04-26 — — CN disclosed
WO-2024028795-A1 HETEROBICYCLIC COMPOUNDS AS ORAL GLP1R AGONISTS ZYDUS LIFESCIENCES LIMITED (IN) 2024-02-08 — — WO disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20220041597-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2022-02-10 — — US disclosed
US-20220041597-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2022-02-10 — — US disclosed
US-20210346356-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2021-11-11 — — US disclosed
EP-3902533-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-11-03 — — EP disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 — — EP disclosed
EP-3852792-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 — — EP disclosed
WO-2020191022-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-09-24 — — WO disclosed
WO-2020139916-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-07-02 — — WO disclosed
WO-2020139916-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-07-02 — — WO disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
WO-2020061252-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
WO-2016046837-A1 AN IMPROVED PROCESS FOR PREPARATION OF PYRROLO[3,4- C] PYRROLE COMPOUNDS AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2016-03-31 — — WO disclosed
WO-2016046837-A1 AN IMPROVED PROCESS FOR PREPARATION OF PYRROLO[3,4- C] PYRROLE COMPOUNDS AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2016-03-31 — — WO disclosed
US-20110245263-A1 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD SANOFI-AVENTIS (FR) 2011-10-06 — — US disclosed
US-8003677-B2 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors SANOFI-AVENTIS (FR) 2011-08-23 — — US disclosed
US-20100144594-A1 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS SANOFI-AVENTIS (FR) 2010-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346356-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, RBX1, USP19 USP2 10/4885SMN1; SMN2 3049/4885ESR2 2588/4885
US-20100144594-A1 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS SCD, SCD5, PYCR1 USP2 4646/4885SMN1; SMN2 1541/4885ESR2 2950/4885
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 USP2 8/4885SMN1; SMN2 2110/4885ESR2 1874/4885
US-20110245263-A1 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD SCD, SCD5, PYCR1 USP2 4676/4885SMN1; SMN2 1387/4885ESR2 2099/4885
US-20220041597-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X MCL1, HSPA9, USP10 USP2 147/4885SMN1; SMN2 4349/4885ESR2 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.